MedTrace Logo

Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea

NCT01016782 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 867

Last updated 2014-07-04

No results posted yet for this study

Summary

The aim of this trial is to assess the efficacy of Metronidazole Topical Gel 1% in the Treatment of Inflammatory Lesions of Rosacea.

Treatment medication will be administered as follows: A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days.

Conditions

  • Inflammatory Rosacea

Interventions

DRUG

0444

A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days

Sponsors & Collaborators

  • Fougera Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Angela C Kaplan · Fougera Pharmaceuticals Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-07-31
Completion
2009-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01016782 on ClinicalTrials.gov